Big Pharma's Biosimilar Stalling Tactics Coming to an End
Specialty Pharmacy Times | May 08, 2017
Historically, traditional small molecule products were the focus of the pharmaceutical industry. This was especially the case between 2010 and 2013, when many of the blockbuster brand name medications—those grossing more than $1 billion in annual sales—lost their patent protection.